EE200300465A - Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid - Google Patents

Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid

Info

Publication number
EE200300465A
EE200300465A EEP200300465A EEP200300465A EE200300465A EE 200300465 A EE200300465 A EE 200300465A EE P200300465 A EEP200300465 A EE P200300465A EE P200300465 A EEP200300465 A EE P200300465A EE 200300465 A EE200300465 A EE 200300465A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
compositions based
pyridoindolone derivatives
pyridoindolone
derivatives
Prior art date
Application number
EEP200300465A
Other languages
English (en)
Estonian (et)
Inventor
Bourrie Bernard
Casellas Pierre
Derocq Jean-Marie
Original Assignee
Sanofi-Synthlabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthlabo filed Critical Sanofi-Synthlabo
Publication of EE200300465A publication Critical patent/EE200300465A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300465A 2001-04-27 2002-04-26 Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid EE200300465A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone
PCT/FR2002/001450 WO2002087575A1 (fr) 2001-04-27 2002-04-26 Associations pharmaceutiques a base de derives de pyridoindolone et d'agents anticancereux

Publications (1)

Publication Number Publication Date
EE200300465A true EE200300465A (et) 2003-12-15

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200300465A EE200300465A (et) 2001-04-27 2002-04-26 Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
EEP200300466A EE200300466A (et) 2001-04-27 2002-04-26 Püridoindolooni derivaatide kasutamine ravimite valmistamiseks

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP200300466A EE200300466A (et) 2001-04-27 2002-04-26 Püridoindolooni derivaatide kasutamine ravimite valmistamiseks

Country Status (34)

Country Link
US (3) US7524857B2 (de)
EP (2) EP1385512B1 (de)
JP (2) JP2004531538A (de)
KR (1) KR100847413B1 (de)
CN (2) CN1240382C (de)
AR (1) AR034313A1 (de)
AT (2) ATE338548T1 (de)
BG (2) BG108260A (de)
BR (1) BR0209138A (de)
CA (2) CA2444334A1 (de)
CY (1) CY1105813T1 (de)
CZ (2) CZ295224B6 (de)
DE (2) DE60214533T2 (de)
DK (2) DK1385512T3 (de)
EA (1) EA005930B1 (de)
EE (2) EE200300465A (de)
ES (2) ES2271264T3 (de)
FR (1) FR2823975B1 (de)
HK (2) HK1059895A1 (de)
HU (2) HUP0400744A2 (de)
IL (4) IL158312A0 (de)
IS (1) IS2441B (de)
MX (1) MXPA03009639A (de)
NO (2) NO20034787L (de)
NZ (1) NZ528671A (de)
PL (2) PL366910A1 (de)
PT (2) PT1385512E (de)
RS (2) RS50791B (de)
RU (1) RU2292888C9 (de)
SK (2) SK13242003A3 (de)
TW (1) TWI252104B (de)
UA (1) UA74876C2 (de)
WO (2) WO2002087574A2 (de)
ZA (1) ZA200307785B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) * 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0755454B1 (de) * 1994-04-13 2008-02-13 The Rockefeller University Aav-vermittelte überbringung von dna in zellen des nervensystems
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
FR2765582B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
WO1999051597A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CZ20032909A3 (en) 2004-06-16
WO2002087575A1 (fr) 2002-11-07
DE60214533D1 (de) 2006-10-19
RS50791B (sr) 2010-08-31
EP1385513B1 (de) 2006-09-06
DE60214533T2 (de) 2007-06-21
WO2002087574A3 (fr) 2003-02-13
CA2443012A1 (en) 2002-11-07
KR20040015138A (ko) 2004-02-18
NO20034787L (no) 2003-12-23
AR034313A1 (es) 2004-02-18
CZ299465B6 (cs) 2008-08-06
IL158266A0 (en) 2004-05-12
IS6984A (is) 2003-10-09
JP2004531538A (ja) 2004-10-14
FR2823975B1 (fr) 2003-05-30
EA005930B1 (ru) 2005-08-25
CZ20032910A3 (en) 2004-07-14
FR2823975A1 (fr) 2002-10-31
US6967203B2 (en) 2005-11-22
DE60208365T2 (de) 2006-09-07
UA74876C2 (en) 2006-02-15
IS2441B (is) 2008-11-15
IL158312A (en) 2009-09-01
DK1385513T3 (da) 2007-01-15
YU83903A (sh) 2006-08-17
CN1240382C (zh) 2006-02-08
US7524857B2 (en) 2009-04-28
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
NZ528671A (en) 2004-06-25
IL158312A0 (en) 2004-05-12
EP1385513A1 (de) 2004-02-04
EP1385512B1 (de) 2005-12-28
HUP0400744A2 (hu) 2004-06-28
CA2444334A1 (fr) 2002-11-07
PT1385513E (pt) 2007-01-31
IL158266A (en) 2009-09-01
YU83403A (sh) 2006-08-17
JP2004528343A (ja) 2004-09-16
RU2003130376A (ru) 2005-04-10
ES2254683T3 (es) 2006-06-16
RS50790B (sr) 2010-08-31
HK1059895A1 (en) 2004-07-23
US20050272760A1 (en) 2005-12-08
KR100847413B1 (ko) 2008-07-18
PL366916A1 (en) 2005-02-07
EA200301062A1 (ru) 2004-04-29
NO20034785D0 (no) 2003-10-24
DK1385512T3 (da) 2006-05-22
SK13242003A3 (sk) 2004-03-02
ZA200307785B (en) 2004-10-06
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
US20040122027A1 (en) 2004-06-24
HK1060066A1 (en) 2004-07-30
ATE314070T1 (de) 2006-01-15
CY1105813T1 (el) 2011-02-02
CN1505510A (zh) 2004-06-16
EP1385512A2 (de) 2004-02-04
DE60208365D1 (de) 2006-02-02
PT1385512E (pt) 2006-05-31
US20040122036A1 (en) 2004-06-24
BG108260A (bg) 2004-12-30
CN1505511A (zh) 2004-06-16
HUP0400745A2 (hu) 2004-08-30
CA2443012C (fr) 2009-07-28
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07
CZ295224B6 (cs) 2005-06-15
SK13252003A3 (sk) 2004-03-02
US7160895B2 (en) 2007-01-09
PL366910A1 (en) 2005-02-07
ES2271264T3 (es) 2007-04-16
EE200300466A (et) 2003-12-15
RU2292888C2 (ru) 2007-02-10
MXPA03009639A (es) 2004-06-30
NO20034787D0 (no) 2003-10-24
BR0209138A (pt) 2004-06-08

Similar Documents

Publication Publication Date Title
FI20011478A0 (fi) Farmaseuttinen koostumus
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
NO20033384L (no) Farmasoytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
ITMI20010748A0 (it) Composizioni farmaceutiche
ATE319451T1 (de) Tetrahydrochinolin-derivate
NO20033785D0 (no) Farmasöytisk formulering
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
PT1501534E (pt) Formulacoes farmaceuticas
PT1242087E (pt) Composicoes farmaceuticas
NO20040125L (no) Enterale formuleringer
EE200300589A (et) Ravimkoostised
NO20035627D0 (no) Farmasöytisk formulering
NO20026123L (no) Farmasöytiske sammensetninger
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
FI20022128A0 (fi) Farmaseuttinen koostumus
PT1239832E (pt) Composicoes farmaceuticas
NO20031095L (no) Farmasoytiske sammensetninger
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DE60202381D1 (de) Paroxetin-n-formyl-derivate
NO20044164L (no) Farmasoytiske sammensetninger
EE200200689A (et) Ravimkoostised

Legal Events

Date Code Title Description
HC1A Change of owner name